Phase I, Double Blind, Randomized, Placebo-Controlled Trial to Examine the Safety, Tolerability and Plasma Pharmacokinetics of Multiple (Monthly) Intramuscular and Subcutaneous Doses of TMC278LA.
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2010
At a glance
- Drugs Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen R&D Ireland
- 25 Oct 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2009 Planned end date changed from 1 Apr 2010 to 1 Nov 2009 as reported by ClinicalTrials.gov.